Rubius Therapeutics to Participate in 7th Annual Jefferies Cell Therapy Summit
Rubius Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: RUBY), will have its Chief Scientific Officer, Laurence Turka, M.D., participating in a fireside chat at the 7th Annual Jefferies Cell Therapy Summit on October 5, 2020, at 4:00 p.m. ET. The event will be accessible via a live audio webcast on the company's website, with an archived replay available for 90 days post-event. Rubius is focused on developing Red Cell Therapeutics™ for treating cancer and autoimmune diseases using its proprietary RED PLATFORM® technology.
- None.
- None.
CAMBRIDGE, Mass., Sept. 29, 2020 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines, today announced that Laurence Turka, M.D., chief scientific officer, will participate in a fireside chat at the 7th Annual Jefferies Cell Therapy Summit on Monday, October 5, 2020, at 4:00 p.m. ET.
A live audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.
About Rubius Therapeutics
Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.
Contacts:
Investors
Lori Melançon
Vice President, Corporate Communications and Investor Relations
+1 (617) 949-5296
lori.melancon@rubiustx.com
Media
Marissa Hanify
Director, Corporate Communications
marissa.hanify@rubiustx.com
Dan Budwick
1AB
+1 (973) 271-6085
dan@1abmedia.com
FAQ
When is Rubius Therapeutics participating in the Jefferies Cell Therapy Summit?
Who is representing Rubius Therapeutics at the summit?
What is the focus of Rubius Therapeutics?
How can I access the Rubius Therapeutics presentation?
Is there a replay available for the Rubius Therapeutics presentation?
